- Pfizer announced that the Food and Drug Administration (FDA) accepted its application for a three-dose COVID-19 vaccine in children aged 6 months to under 5 years old. In February, the FDA asked Pfizer-BioNTech to submit a request for emergency use authorization (EUA) based on the two-dose data but then postponed a meeting of its vaccine advisory committee so the third-dose data could be considered. The committee will meet on June 15 to discuss Moderna and Pfizer’s EUA requests for vaccines for younger children. (Articles here, here, and here)
June 2, 2022
Life Sciences